Patent application number | Description | Published |
20130211050 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 08-15-2013 |
20130309239 | ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 11-21-2013 |
20150273027 | LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE - The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VIIa polypeptide, a buffering agent suitable for keeping pH in the range of from about 5.5 to about 8.5; and an active site stabilizing agent, which is selected from the group of: (S)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2′-dihydroxy-5′-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; (R)-2-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2′-dihydroxy-5′-sulfamoyl-biphenyl-3-yl]acetylamino}-succinic acid or a pharmaceutically acceptable salt thereof; and a mixture of the (S)- and (R)-forms or pharmaceutically acceptable salts thereof. The invention further relates to said composition for treatment of a Factor VII-responsive bleeding disorder; methods for preparing the liquid composition and for stabilizing Factor VIIa in a liquid aqueous composition; an air-tight container containing the liquid, aqueous pharmaceutical composition and optionally an inert gas; and a method of treating a Factor VII-responsive bleeding disorder in a patent. | 10-01-2015 |
20150274825 | Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 10-01-2015 |
Patent application number | Description | Published |
20110178985 | MASTER MONITORING MECHANISM FOR A GEOGRAPHICAL DISTRIBUTED DATABASE - The present invention faces the issue of data replication in different database nodes of a geographically distributed database wherein clients cannot always perform any database-related operation in the closest database node. Thus, the present invention provides for an enhanced distributed database system with a plurality of nodes, each node arranged for storing a replica of at least one partition of data, and a method of handling said distributed database system comprising the steps of: partitioning data to a number of partitions; replicating each partition into a number of replicas; for each partition, distributing the number of replicas amongst database nodes; activating more than one node; monitoring at each active node events of: latest updating of each replica, replica status, status of local resources in charge of each replica, and connectivity status of each replica; upon activation o deactivation of a node, determining which node is considered current master node for each partition in charge of current mast replica; for any request received in a node to read/write data, determining the current master node in charge of the current master replica, and routing said request to said current master node. | 07-21-2011 |
20110188506 | Distributed Master Election - A transmitting node in a telecommunications network, wherein data are distributed into one or more data storage groups (DSG), and wherein data related to a DSG is replicated into a plurality of data storage elements (DS) distributed along one or more nodes of the network. The transmitting node includes a network interface through which a bi-directional connection is established with a plurality of other nodes in a transport layer of the network, and from which messages are sent to the plurality of other nodes comprising an operational state matrix (OSM), which includes information held by the transmitting node about the operational state of the replicas of the DSs of each DSG. The transmitting node includes a memory for storing data. The transmitting node includes a processing unit which forms a list of the plurality of other nodes as having an answer pending of the node in the memory. The network interface receives an OSM from at least some of other nodes which are interpreted by the processing unit as answer messages from the list of the plurality of other nodes to the messages sent by the network interface, and which indicates that an OSM information exchange with the plurality of the other nodes is complete. The processing unit decides a node hosting the master DS replica of each DSG based on the OSM information exchange. The processing unit detects changes in a view of the world (VOW) which includes an accumulated set of OSMs with respect to each DSG hosted by the transmitting node. The network interface sends messages comprising changes in the VOW to the other nodes. | 08-04-2011 |
Patent application number | Description | Published |
20100310096 | Switchable Attenuation Circuit for MEMS Microphone Systems - A switch control circuit monitors a signal produced by a MEMS or other capacitor microphone. When a criterion is met, for example when the amplitude of the monitored signal exceeds a threshold or the monitored signal has been clipped or analysis of the monitored signal indicates clipping is imminent or likely, the switch control circuit operates one or more switches so as to selectively connect one or more capacitors to a signal line from the microphone, i.e., so as to connect a selected capacitance to the signal line to attenuate the signal from the microphone and, therefore, avoid clipping. The switches may be MOSFET, MEMS or other types of switches co-located with the microphone in a common semiconductor package. Similarly, the capacitors, a circuit that processes the signals from the microphone and/or the switch control circuit may be co-located with the microphone in a common semiconductor package. | 12-09-2010 |
20140093102 | SWITCHABLE ATTENUATION CIRCUIT FOR MEMS MICROPHONE SY - A switch control circuit monitors a signal produced by a MEMS or other capacitor microphone. When a criterion is met, for example when the amplitude of the monitored signal exceeds a threshold or the monitored signal has been clipped or analysis of the monitored signal indicates clipping is imminent or likely, the switch control circuit operates one or more switches so as to selectively connect one or more capacitors to a signal line from the microphone, i.e., so as to connect a selected capacitance to the signal line to attenuate the signal from the microphone and, therefore, avoid clipping. The switches may be MOSFET, MEMS or other types of switches co-located with the microphone in a common semiconductor package. Similarly, the capacitors, a circuit that processes the signals from the microphone and/or the switch control circuit may be co-located with the microphone in a common semiconductor package. | 04-03-2014 |
Patent application number | Description | Published |
20120009243 | LIPOSOMES FOR DRUG DELIVERY AND METHODS FOR PREPARATION THEREOF - The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention. | 01-12-2012 |
20120213698 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES - The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications. | 08-23-2012 |
20130251630 | Entrapment of Radionuclides in Nanoparticle Compositions - The present invention is directed to the technical field of imaging compositions useful for diagnosing cancer and other diseases in a subject. In particular, the invention relates to a class of diagnostic compounds comprising a novel liposome composition with encapsulated metal entities such as radionuclides, for example | 09-26-2013 |
20140328897 | CHARGE TRIGGERING OF SELF-ORGANIZED NANOPARTICLES - The present application discloses a nanoparticle comprising compounds of the formula A-B-C(-D), wherein A designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; B designates a cleavable linker; C designates an anionic moiety having a net charge of at least −2 at pH 6.0; and D, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least −1 at pH 6.0. The application also discloses the individual compounds of the formula A-B-C(-D) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal. | 11-06-2014 |
20150079155 | Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood - This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, T-lymphocytes, B-lymphocytes and/or NK cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy. | 03-19-2015 |
20150202336 | Loading Technique for Preparing Radionuclide Containing Nanoparticles - The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications. | 07-23-2015 |
Patent application number | Description | Published |
20100093014 | SCREENING FOR BONE ANABOLIC FACTORS - A method for screening for modulators of the secretion by an osteoclast of a wnt or a wnt signal enhancer comprises exposing osteoclasts in culture to a compound to be screened, exposing a wnt sensitive detection system to conditioned medium from said osteoclast culture, and determining whether a wnt signal is present in said medium by assaying for wnt mediated activation of bone formation by osteoblasts or by wnt mediated activation of LRP5 and or LPR6 signalling in a cell by detection of β catenin or detection of translocation of disheveled, axin, or Frat1 to the cell membrane of said cell. | 04-15-2010 |
20130109620 | BALAGLITAZONE COMPOSITIONS AND METHODS | 05-02-2013 |
20130183385 | PEPTIDE ANALOGS FOR TREATING DISEASES AND DISORDERS - A peptide having a sequence selected from SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18. Said peptide used for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test. | 07-18-2013 |
20150064726 | Biochemical Markers for Neurodegenerative Conditions - A method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions comprising a neo-epitope formed by cleavage of a Tau protein by a secretase such as ADAM10 comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function. | 03-05-2015 |
20150196617 | Peptide Analogs for Treating Diseases and Disorders - Provided herein are methods for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. Treatment is effected with a combination therapy of metformin and a peptide with a sequence selected from SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24 administered to a patient. | 07-16-2015 |
Patent application number | Description | Published |
20130117060 | System for Collaboration and Meeting Management - Computer hardware and software implement a mind mapping system and method for collaboration. Each branch is assigned an identifier by the system, and each child branch is assigned a child identifier. The child identifier includes a reference to the identifier of the branch from which the child branch extends. An external export system may export information to external project management systems. An input system may receive changes to parameters, determining if changes should be made and rejecting changes for lack of permissions. A system may automatically generate a meeting agenda from tasks that may be created during mind mapping incorporating automatic generation of a meeting agenda, automatic optimization of the meeting agenda, automatic conduct of a meeting and automatic generation of a dashboard including information obtained from the system and feedback and switching between viewing projects in a mind map agenda view or a project management view. | 05-09-2013 |
20140108085 | DETECTION AND RESCHEDULING OF UNADDRESSED TOPICS WITH THE MEETING MANAGEMENT SYSTEM - A computer software for managing electronic meetings. The meeting management system automatically detects and classifies unaddressed topics. A topic is classified as unaddressed when its actual duration is less than a predefined minimum duration, the notes for the topic do not satisfy predefined criteria, and the topic does not have a conclusion statement. The user can directly classifying a topic as unaddressed. Upon completion of the meeting, the system presents a listing of unaddressed topics to the user. The system can also reschedule the unaddressed topics for a follow-up meeting. | 04-17-2014 |
20140149166 | TOPIC DISTRIBUTION WITHIN A MEETING MANAGEMENT SYSTEM - Computer hardware and software implement a mind mapping system and method for collaboration. Each branch is assigned an identifier by the system, and each child branch is assigned a child identifier. The child identifier includes a reference to the identifier of the branch from which the child branch extends. An external export system may export information to external project management systems. An input system may receive changes to parameters, determining if changes should be made and rejecting changes for lack of permissions. A system may automatically generate a meeting agenda from tasks that may be created during mind mapping incorporating automatic generation of a meeting agenda, automatic optimization of the meeting agenda, automatic conduct of a meeting and automatic generation of a dashboard including information obtained from the system and feedback and switching between viewing projects in a mind map agenda view or a project management view. | 05-29-2014 |
20140200944 | AUTOMATION OF MEETING SCHEDULING AND TASK LIST ACCESS PERMISSIONS WITHIN A MEETING SERIES - A computer software for managing electronic meetings. The meeting management system includes a Meeting Series feature. Individual meetings with at least one common characteristic may be grouped into a Meeting Series. The Meeting Series has a number of users/members associated with the entire Meeting Series and each individual meeting within the Meeting Series. Each meeting has a plurality of tasks associated with the meeting. The tasks are assigned to members. The members can access the task list for an individual meeting or the entire Meeting Series. The task list is dynamic and filtered based on the predefined permission rules. New meetings within the Meeting Series may be scheduled manually or automatically based on the status of the tasks associated with the Meeting Series. The list of members invited to each new meeting is prepopulated based on their membership within the Meeting Series and the status of the task assigned to them. | 07-17-2014 |